A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology—boosting productivity, identifying life-threatening conditions in milliseconds ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).

Neonatal hepatitis (NH) and biliary atresia are two separate conditions that can affect infants and share specific symptoms, such as liver damage. Read more.

Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.

A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with HER2 ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.